Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Syndax Pharmaceuticals, Inc. - Common Stock
(NQ:
SNDX
)
13.65
+0.12 (+0.89%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Syndax Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
Next >
Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
Today 16:01 EDT
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
October 12, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 02, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Announces Participation in September Investor Conferences
September 01, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 05, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
August 04, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
July 28, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
July 14, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 01, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
June 11, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
June 11, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
June 04, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
June 04, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
June 02, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
June 01, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
May 21, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Announces Participation in Upcoming Investor Conferences
May 20, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
May 12, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 06, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
April 30, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
April 24, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 03, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
March 04, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Announces Participation in March Investor Conferences
February 23, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026
February 19, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit
February 05, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 04, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
January 07, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
